All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XT-150
Therapeutic Area: Musculoskeletal Product Name: XT-150
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
XT-150 is currently in a Phase II/III trial for osteoarthritis, and Nguyen expects to read out topline Phase IIb data in Q4. XT-150, is a locally injectable plasmid DNA gene therapy expressing Interleukin 10 (IL-10).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Diclofenac Sodium
Therapeutic Area: Musculoskeletal Product Name: AMZ001
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020
Details:
This phase 2/3 multi-center, randomized, double-blind trial investigated the effect of a new 3.06% diclofenac sodium gel formulation (AMZ001) for the relief of knee OA pain, in 444 patients exposed to either AMZ001 once daily (QD), AMZ001 twice daily (BID) or placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
Details:
Two studies are the pivotal JTA-004 Ph III clinical study targeting osteoarthritic knee pain and Ph IIb study of its allogeneic cell therapy product, ALLOB, in difficult tibial fractures.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
